Strata Critical Medical Reports 60.7% Revenue Growth to $72.5 Million in Q2 2026

Strata Critical Medical, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $72.5 million for the three months ended June 30, 2026, a 60.7% increase from $45.1 million in the same period last year. For the first half of 2026, revenue surged to $139.9 million, up 72.6% from $81.1 million in the prior year. The growth was driven by a combination of increased logistics revenue, which rose 6.9% to $48.2 million, and the newly established clinical segment, which generated $24.3 million following the acquisition of Keystone Perfusion Services in September 2025.

Despite the revenue increase, Strata reported a net loss of $10.5 million for the second quarter, compared to a loss of $3.4 million in the same period last year. The company attributed the increased losses to higher operating expenses, which rose to $20.6 million from $13.6 million year-over-year, largely due to elevated costs associated with the integration of acquired businesses and increased amortization of intangible assets. The operating loss from continuing operations was $5.4 million for the quarter, reflecting a slight increase from the previous year's loss of $4.6 million.

Strategically, Strata has been active in expanding its service offerings through acquisitions. In addition to the Keystone acquisition, the company completed three additional acquisitions in 2026, including Ohio Valley Perfusion Associates, Louisville Perfusion Services, and Heart and Lung Transplant National Recovery Program. These acquisitions are part of Strata's strategy to enhance its clinical services and expand its geographic reach in the transplant industry. The company also reported a significant increase in its intangible assets, which rose to $60 million from $47.5 million, reflecting the value of the acquired businesses.

Operationally, Strata's total assets increased to $332.7 million as of June 30, 2026, up from $325.5 million at the end of 2025. The company reported a total employee headcount of 1,200, reflecting its growth and expansion efforts. However, cash and cash equivalents decreased to $16.3 million from $31 million, primarily due to cash used in investing activities related to acquisitions. The company also established a new asset-based revolving credit facility in January 2026, providing up to $30 million in additional liquidity.

Looking ahead, Strata remains focused on leveraging its expanded service offerings and operational capabilities to drive future growth. The company anticipates that the integration of its recent acquisitions will enhance its competitive position in the market, particularly in the logistics and clinical segments. However, Strata acknowledges the ongoing challenges in the healthcare and aviation sectors, including potential fluctuations in organ donation rates and the need to maintain high-quality service standards to attract and retain customers.